Skip to main content

Table 2 Clinical trials studies on CRISPR/Cas9 in different type of cancer

From: CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics

Target Cancer type Stage of testing Reference
CISH gene within tumor-infiltrating lymphocytes inactivated by CRISPR/Cas9 Metastatic gastrointestinal epithelial cancer Phase II NCT03538613
PD1 knockout engineered T- cells Advanced esophageal cancer Phase II NCT03081715
PD-1 knockout EBV-CTLs Advanced stage Epstein–Barr virus (EBV) associated malignancies Phase II NCT03044743
Gene-disrupted allogeneic CD19-directed BBζ CAR-T cells (UCART019) Relapsed or refractory CD19+ leukemia and lymphoma Phase II NCT03166878
Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy Relapsed or refractory leukemia and lymphoma Phase II NCT03398967
PD-1 and TCR gene-knocked out mesothelin-directed CAR-T cells Mesothelin positive multiple solid tumors Phase I NCT03545815
PD-1 knockout engineered T Cells Metastatic non-small cell lung cancer Phase I NCT02793856
NY-ESO-1-redirected CRISPR (TCRendo and PD1) edited T-cells (NYCE T-cells) Multiple myeloma melanoma synovial sarcoma myxoid/round cell liposarcoma Phase I NCT03399448